Vertex Pharmaceuticals (VRTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-17. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 9/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 1.78% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Upcoming Catalysts
- VRTX (Vertex Pharmaceuticals) — PDUFA date 2026-11-30
Recent News & SEC Filings
- What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders
- Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data
- Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
- Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts
- Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders
- What You Need to Know Ahead of Vertex Pharmaceuticals’ Earnings Release
- Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
- Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Vertex Pharmaceuticals.
Full VRTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.